Andy has 30 years of experience in the pharmaceutical industry and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in April 2012. He is the head of Medicago New Ventures and was formerly President and Chief Executive Officer of Medicago Inc. Before joining Medicago Inc. in 2003, Mr. Sheldon served as Vice President, Sales and Marketing, of Shire Biologics and as General Manager of Rhône Merieux Canada. Mr. Sheldon is also the Board Chairman of Quebec International in the Quebec City region. Mr. Sheldon has a Bachelors degree in agricultural sciences from the Université Laval, Québec City, and a bachelor’s of science degree with honors in biological sciences from the University of East Anglia, in Norwich, England.Back to Top
Julia P. Gregory is a seasoned biotechnology executive with a proven track record for successfully growing, capitalizing and repositioning private and public biotechnology companies. She is well-versed in corporate governance and SEC issues and has extensive experience in recruiting outstanding management teams. As a biotechnology executive, she has raised more than $1.5 billion for biotechnology companies across all types of business cycles and structured creative strategic alliances and transactions for them with pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Genentech, Inc. (now Roche) and Human Genome Sciences (now GSK). Most recently, she was CEO and Board member of ContraFect (NASDAQ: CFRX), which focused on new biologics as an alternative to antibiotics. Prior to ContraFect, she was CEO and Board member of FivePrime Therapeutics (NASDAQ: FXRX), which discovered and developed innovative protein and antibody therapeutics in the fields of oncology and immunology. She was the EVP Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) during its $220 million initial public offering and was involved in the creation of Lexicon’s $500 million private equity investment plan. In addition to her deep experience in the biopharmaceutical industry, Ms. Gregory has twenty years of investment banking experience, starting at Dillon, Read & Co., Inc. and subsequently at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice. Ms. Gregory has also served on the Board of Directors at The Global TB Alliance for Drug Development, Clinipace Worldwide, and the Institute for the Study of Aging, a private foundation for Alzheimers. She is currently a Director at Iconic Therapeutics, the Sosei Group Corporation and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN). Ms. Gregory attained a Masters of Business Administration from The Wharton School of The University of Pennsylvania and her B.A. in International Affairs from George Washington University’s Elliott School of International Affairs where she was elected to Phi Beta Kappa.Back to Top
James is an experienced, knowledgeable and versatile entrepreneur, business operator, corporate investor, director and advisor with expertise in finance (accounting/restructurings/special investigations), private equity, banking and media. He is currently President of James Hall Advisors Inc. – financial and management consultants – and was formerly Vice President of Callidus Capital Corporation (a stressed asset-based lender operating in Canada and the United States). Prior to Callidus, he served as Chairman and CEO of Journal Register Company (Philadelphia-based newspaper company), and was Senior Vice President and Chief Investment Officer of Working Ventures Canadian Fun Inc. from 1990 to 2002. Past corporate directorships include Indigo Books & Music Inc., Atomic Energy of Canada Limited, TerraVest Income Fun, General Donlee Income Fund and international Datacasting Corporation. A Chartered Professional Accountant. Mr. Hall is a graduate of the Richard Ivey School of Business at Western University in London, Ontario.Back to Top
Fred has served as our Chief Executive Officer since April 2016. As CEO, He has led the transformation of IMV into a leading clinical stage immune oncology company with world-class collaborators and a strong scientific foundation.
He has over 20 years of experience in the biopharmaceutical industry, having served in a number of management roles encompassing business development, intellectual property, strategic planning, pre-marketing and communication. Before joining IMV, Fred spent 14 years at Medicago serving in many roles of increasing responsibility, most recently as Vice President of Business Development and Strategic Planning. He had been an integral part of Medicago’s success, including securing more than $300M CAN in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts, and the $357M CAN deal acquisition by Mitsubishi Pharma in 2013.
Fred served as second Vice-Chair of the Vaccine Industry Committee of Biotech Canada between 2012 and 2016. Prior to Medicago, he was licensing manager at the University Paris VII-Denis Diderot, one of the largest science and medical University in France. He has a B.Sc. degree in Biology and a Master degree in Management from the University of Angers (France).Back to Top
Wayne has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He joined IMV’s board in October 2011 with a depth of experience across the spectrum of commercial operations, public immunization policies and pipeline development. Wayne is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He joined Sanofi Pasteur in 1997 and was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. Post his retirement from Sanofi Pasteur, Wayne joined VaxInnate, a privately held biotech company, from January 2012 until November 2016 serving as President and CEO.
During his tenure as CEO of Sanofi Pasteur, Wayne bolstered the pipeline with the acquisitions of Acambis PLC, a bio-tech based in Boston in 2008 and Shantha Biotechnics, a highly regarded Indian vaccine company in 2010. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a BS in Biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.
Albert is a technology and media investor. He has extensive experience as a director of both for-profit and not-for-profit organizations, public and private, in the United States and the United Kingdom. He was a correspondent, commentator and editor for The New York Times, The Guardian, The Independent, the BBC and Sky News. He has served as a communications director in political campaigns and government. He earned his Bachelor’s degree at Columbia University and his Master’s at the University of California, Berkeley. He has been an investor in IMV since 2005, a director since 2010 and was Chairman of the Board from 2011-2016.Back to Top
Fred is the President and Chief Executive Officer of Iona Resources Holdings Limited. He was founder and former President and Chief Executive Officer of the Secunda Group of Companies. For six consecutive years, Deloitte & Touche named Secunda Marine Limited one of the “50 Best Managed Companies in Canada.” Fred sold Secunda Marine Services to J. Ray McDermott, an NYSE-listed company, in 2007. In 2003, Fred was named one of the “Top 50 CEOs of Atlantic Canada,” and is a member of the Nova Scotia Business Hall of Fame. He received an Honorary Diploma from the Nova Scotia Community College and holds an Honorary Doctorate in Commerce from Saint Mary’s University. With a history of past board appointments, Fred currently sits on the Board of Directors of the Dartmouth General Hospital and the Advisory Board of Atlantic Signature Mortgage & Loan. He is a recipient of the Canadian Red Cross Humanitarian Award, an Officer of the Order of Canada and the Honorary British Consul.Back to Top
Shermaine is a Managing Partner at CTI Life Sciences Fund (CTI LSF), a Montreal-based venture capital fund investing across Canada as well as in the United States. CTI LSF currently has $245M under management, comprised of 2014 vintage Fund II that is open for investment as well as a 2006 vintage Fund I. Since joining CTI LSF at its inception in 2006, Shermaine has played a critical role in each of the investments made by the Fund, but particularly by leading investments in Medicago–acquired by Mitsubishi Tanabe in 2013–as well as those in Phemi, Xagenic and Zymeworks. She was also a board observer in Enobia that was acquired by Alexion in 2012 in the largest takeout of a private development-stage biotech for $1.1B, assuming all milestones are received. Prior to joining CTI LSF in 2006, Shermain was Senior Vice President at Drug Royalty Corporation, the world’s first private equity firm doing royalty transactions in the biotech/pharma space. At DRC (now DRI), she played a leading role in closing 12 transactions totaling over $200M in investments. Before DRC, Shermaine managed a research laboratory, holding faculty positions at the NYU School of Medicine and Public Health Research Institute, NY, and on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the NIH Small Business Innovation Research (SBIR) program in immunology and infectious disease for 10 years. Shermaine holds a PhD in biochemistry from the Johns Hopkins University School of Medicine, an MBA from the University of Toronto and is a member of the CFA Society of Toronto. She currently sits on the boards of Phemi, Xagenic, Zymeworks and BIOTECanada.Back to Top Back to Top
Working at IMV brings you to the forefront of cutting-edge science and research for cancer and other serious diseases. We’ve worked hard to build a culture of innovation and collaboration.Learn more about life at IMV